



Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

November 10, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17 at 9:40 AM ET.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/news-events/events-presentations>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line GIST. QINLOCK is also approved in Canada and Australia for fourth-line GIST. For more information, visit www.Deciphera.com and follow us on Twitter (@Deciphera) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201110005273/en/): <https://www.businesswire.com/news/home/20201110005273/en/>

Investor Relations:

Jen Robinson
Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com
781-906-1112

Media:

David Rosen
Argot Partners
David.Rosen@argotpartners.com
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.